Advanced search
Publication Cover
Epigenomics Volume 4, 2012 - Issue 4
Submit an article Journal homepage
381
Views
0
CrossRef citations to date
0
Altmetric
Review

miRNAs as Mediators of Drug Resistance

Sierk Haenisch1 Institute of Experimental&Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Street 3, Building 30, D-24105 Kiel, Germany
&
Ingolf Cascorbi1 Institute of Experimental&Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Street 3, Building 30, D-24105 Kiel, GermanyCorrespondence[email protected]
Pages 369-381 | Published online: 24 Aug 2012

References

  • Szyf M . The early life social environment and DNA methylation: DNA methylation mediating the long-term impact of social environments early in life. Epigenetics6(8) , 971–978 (2011).
  • Lima SC , Hernandez-VargasH, HercegZ. Epigenetic signatures in cancer: implications for the control of cancer in the clinic. Curr. Opin. Mol. Ther.12(3) , 316–324 (2010).
  • Pirola L , BalcerczykA, OkabeJ, El-OstaA. Epigenetic phenomena linked to diabetic complications. Nat. Rev. Endocrinol.6(12) , 665–675 (2010).
  • Marques SC , OliveiraCR, PereiraCM, OuteiroTF. Epigenetics in neurodegeneration: a new layer of complexity. Prog. Neuropsychopharmacol. Biol. Psychiatry35(2) , 348–355 (2011).
  • Dong E , GraysonDR, GuidottiA, CostaE. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics1(1) , 201–211 (2009).
  • Crea F , NobiliS, PaolicchiE et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14(6) , 280–296 (2011).
  • Starkey Lewis PJ , DearJ, PlattV et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5) , 1767–1776 (2011).
  • Hashimoto H , TakamiY, SonodaE et al. Histone H1 null vertebrate cells exhibit altered nucleosome architecture. Nucleic Acids Res. 38(11) , 3533–3545 (2010).
  • Sharma S , KellyTK, JonesPA. Epigenetics in cancer. Carcinogenesis31(1) , 27–36 (2010).
  • Kulis M , EstellerM. DNA methylation and cancer. Adv. Genet.70 , 27–56 (2010).
  • Vire E , BrennerC, DeplusR et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078) , 871–874 (2006).
  • Sansom OJ , MaddisonK, ClarkeAR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat. Clin. Pract. Oncol.4(5) , 305–315 (2007).
  • Szyf M . Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol.49 , 243–263 (2009).
  • Suzuki Y , YanagisawaM, ArigaT, YuRK. Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development. J. Neurochem.116(5) , 874–880 (2011).
  • Gore SD . Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol.2(Suppl. 1) , S30–S35 (2005).
  • Mann BS , JohnsonJR, CohenMH, JusticeR, PazdurR. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist12(10) , 1247–1252 (2007).
  • Hrzenjak A , MoinfarF, KremserML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5(9) , 2203–2210 (2006).
  • Mohammed TA , HolenKD, Jaskula-SztulR et al. A pilot Phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 16(6) , 835–843 (2011).
  • Scherpereel A , BerghmansT, LafitteJJ et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A Phase II study. Eur. Respir. J. 37(1) , 129–135 (2011).
  • Thomas S , ThurnKT, BicakuE, MarchionDC, MunsterPN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res. Treat.130(2) , 437–447 (2011).
  • Sekita S , YoshihiraK, NatoriS et al. Mycotoxin production by Chaetomium spp. and related fungi. Can. J. Microbiol. 27(8) , 766–772 (1981).
  • Greiner D , BonaldiT, EskelandR, RoemerE, ImhofA. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9. Nat. Chem. Biol.1(3) , 143–145 (2005).
  • Chaib H , NebbiosoA, PrebetT et al. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia 26(4) , 662–674 (2011).
  • Bernhard W , BarretoK, SaundersA, DahabiehMS, JohnsonP, SadowskiI. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett.585(22) , 3549–3554 (2011).
  • Wang J , LuF, RenQ et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 71(23) , 7238–7249 (2011).
  • Chen Y , JieW, YanW, ZhouK, XiaoY. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Crit Rev. Eukaryot. Gene Expr.22(1) , 53–59 (2012).
  • Singh MM , MantonCA, BhatKP et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro. Oncol. 13(8) , 894–903 (2011).
  • Racz Z , KaucsarT, HamarP. The huge world of small RNAs: regulating networks of microRNAs (review). Acta Physiol Hung.98(3) , 243–251 (2011).
  • Skalsky RL , CullenBR. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol.64 , 123–141 (2010).
  • Wiemer EA . The role of microRNAs in cancer: no small matter. Eur. J. Cancer43(10) , 1529–1544 (2007).
  • Eiring AM , HarbJG, NevianiP et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140(5) , 652–665 (2010).
  • Bao N , LyeKW, BartonMK. MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev. Cell7(5) , 653–662 (2004).
  • Poliseno L , SalmenaL, ZhangJ, CarverB, HavemanWJ, PandolfiPP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature465(7301) , 1033–1038 (2010).
  • Lovat F , ValeriN, CroceCM. MicroRNAs in the pathogenesis of cancer. Semin. Oncol.38(6) , 724–733 (2011).
  • Ferland-McCollough D , OzanneSE, SiddleK, WillisAE, BushellM. The involvement of microRNAs in Type 2 diabetes. Biochem. Soc. Trans.38(6) , 1565–1570 (2010).
  • Salta E , De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol.11(2) , 189–200 (2012).
  • Hatziapostolou M , IliopoulosD. Epigenetic aberrations during oncogenesis. Cell Mol. Life Sci.68(10) , 1681–1702 (2011).
  • Smits M , MirSE, NilssonRJ et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 6(1) , e16282 (2011).
  • Nana-Sinkam SP , CroceCM. Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol. Oncol.5(6) , 483–491 (2011).
  • Kovalchuk O , FilkowskiJ, MeservyJ et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7(7) , 2152–2159 (2008).
  • Li Z , HuS, WangJ et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol. 119(1) , 125–130 (2010).
  • Zhu H , WuH, LiuX et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76(5) , 582–588 (2008).
  • Zhang H , LiM, HanY et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig. Dis. Sci. 55(9) , 2545–2551 (2010).
  • Feng DD , ZhangH, ZhangP et al. Down-regulated miR-331–5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J. Cell Mol. Med. 15(10) , 2164–2175 (2011).
  • Li X , PanYZ, SeigelGM, HuZH, HuangM, YuAM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol.81(6) , 783–792 (2011).
  • Liao R , SunJ, ZhangL et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J. Cell Biochem. 104(3) , 805–817 (2008).
  • Pan YZ , MorrisME, YuAM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol.75(6) , 1374–1379 (2009).
  • To KK , ZhanZ, LitmanT, BatesSE. Regulation of ABCG2 expression at the 3´ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell Biol.28(17) , 5147–5161 (2008).
  • To KK , RobeyRW, KnutsenT, ZhanZ, RiedT, BatesSE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol. Cancer Ther.8(10) , 2959–2968 (2009).
  • Turrini E , HaenischS, LaecheltS, DiewockT, BruhnO, CascorbiI. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet. Genomics22(3) , 198–205 (2012).
  • Liang Z , WuH, XiaJ et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 79(6) , 817–824 (2010).
  • Pogribny IP , FilkowskiJN, TryndyakVP, GolubovA, ShpylevaSI, KovalchukO. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer127(8) , 1785–1794 (2010).
  • Jeon HM , SohnYW, OhSY et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 71(9) , 3410–3421 (2011).
  • Zhu Y , YuF, JiaoY et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res. 17(22) , 7105–7115 (2011).
  • Pan YZ , GaoW, YuAM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos.37(10) , 2112–2117 (2009).
  • Subramanian S , SteerCJ. MicroRNAs as gatekeepers of apoptosis. J. Cell Physiol223(2) , 289–298 (2010).
  • Tomokuni A , EguchiH, TomimaruY et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 414(4) , 675–680 (2011).
  • Wang ZX , LuBB, WangH, ChengZX, YinYM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch. Med. Res.42(4) , 281–290 (2011).
  • Bai H , XuR, CaoZ, WeiD, WangC. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett.585(2) , 402–408 (2011).
  • Gong C , YaoY, WangY et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 286(21) , 19127–19137 (2011).
  • Tarasov V , JungP, VerdoodtB et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6(13) , 1586–1593 (2007).
  • Zenz T , MohrJ, ElderingE et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113(16) , 3801–3808 (2009).
  • Vogt M , MundingJ, GrunerM et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458(3) , 313–322 (2011).
  • Kojima K , FujitaY, NozawaY, DeguchiT, ItoM. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate70(14) , 1501–1512 (2010).
  • le Sage C , NagelR, EganDA et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26(15) , 3699–3708 (2007).
  • Miller TE , GhoshalK, RamaswamyB et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283(44) , 29897–29903 (2008).
  • Zhao JJ , LinJ, YangH et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283(45) , 31079–31086 (2008).
  • Rao X , Di Leva G, Li M et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene30(9) , 1082–1097 (2011).
  • Xia L , ZhangD, DuR et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123(2) , 372–379 (2008).
  • Li H , HuiL, XuW. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim. Biophys. Sin. (Shanghai)44(3) , 269–277 (2012).
  • Zhu W , ShanX, WangT, ShuY, LiuP. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer127(11) , 2520–2529 (2010).
  • Zhu W , XuH, ZhuD et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother. Pharmacol. 69(3) , 723–731 (2012).
  • Zhu W , ZhuD, LuS et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med.Oncol. 29(1) , 384–391 (2012).
  • Gunaratne PH . Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells? Curr. Stem Cell Res. Ther.4(3) , 168–177 (2009).
  • Liu C , TangDG. MicroRNA regulation of cancer stem cells. Cancer Res.71(18) , 5950–5954 (2011).
  • Yu F , YaoH, ZhuP et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6) , 1109–1123 (2007).
  • Shimono Y , ZabalaM, ChoRW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3) , 592–603 (2009).
  • Tryndyak VP , BelandFA, PogribnyIP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer126(11) , 2575–2583 (2010).
  • Choudhry H , CattoJW. Epigenetic regulation of microRNA expression in cancer. Methods Mol. Biol.676 , 165–184 (2011).
  • Rhodes LV , NitschkeAM, SegarHC et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol. Rep. 27(1) , 10–16 (2012).
  • Nalls D , TangSN, RodovaM, SrivastavaRK, ShankarS. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE6(8) , e24099 (2011).
  • Wong KY , YimRL, SoCC, JinDY, LiangR, ChimCS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood118(22) , 5901–5904 (2011).
  • Paik JH , JangJY, JeonYK et al. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin. Cancer Res. 17(14) , 4761–4771 (2011).
  • Scott GK , MattieMD, BergerCE, BenzSC, BenzCC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res.66(3) , 1277–1281 (2006).
  • Li X , LiuJ, ZhouR, HuangS, HuangS, ChenXM. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Br. J. Haematol.148(1) , 69–79 (2010).
  • Bueno MJ , Pérez de Castro I, Gómez de Cedrón M et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell13(6) , 496–506 (2008).
  • Ru P , SteeleR, HsuehEC, RayRB. Anti-miR-203 Upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer2(7) , 720–727 (2011).
  • Zhou R , YuanP, WangY et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34(6) , 1395–1405 (2009).
  • Haenisch S , LaecheltS, BruckmuellerH et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 80(2) , 314–320 (2011).
  • Bao B , WangZ, AliS et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila.) 5(3) , 355–364 (2012).
  • Garzon R , MarcucciG, CroceCM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9(10) , 775–789 (2010).
  • Juergens RA , WrangleJ, VendettiFP et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7) , 598–607 (2011).
  • Moskalev EA , SchubertM, HoheiselJD. RNA-directed epigenomic reprogramming: an emerging principle of a more targeted cancer therapy? Genes Chromosomes. Cancer51(2) , 105–110 (2012).
  • Li Y , GuessousF, ZhangY et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69(19) , 7569–7576 (2009).
  • Yamamura S , SainiS, MajidS et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE 7(1) , e29722 (2012).
  • Shi L , ZhangS, FengK et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int. J. Oncol. 40(1) , 119–129 (2012).
  • Li X , SandaT, LookAT, NovinaCD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J. Exp. Med.208(4) , 663–675 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.